App-Quantinova.ai

Safety, efficacy and tolerability of the NORDIC regimen in the front‐line treatment of transplant‐eligible patients with mantle cell lymphoma

J. Tobin - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Mantle cell lymphoma

Dexamethasone

Combination of Bruton's Tyrosine Kinase (BTK) inhibitor, ibrutinib, with rituximab versus placebo with rituximab in previously untreated patients with follicular lymphoma (FL): a randomized, phase 3 study (Perspective)

S. Rule - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non‐Hodgkin Lymphoma

Ibrutinib

Real world outcomes for treatment of diffuse large B cell Lymphoma in patients aged 80 and over

R. Cooke - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Diffuse large B-cell lymphoma

Dexamethasone

Synchronous dual haematological malignancies: lymphoplasmacytic lymphoma and hairy cell leukaemia

M. Gupta - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Transitional cell carcinoma of the bladder

Dexamethasone

Asian variant intravascular lymphoma – the itinerant impressionist

A. Sridhar - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Real world experience of Ibrutinib at the University Hospital of Wales, Cardiff

E. Hopkins - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ibrutinib

An analysis of patients treated with weekly salvage chemotherapy regimens for high grade lymphoma

S. Sureshkumar - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Lenalidomide with low‐dose dexamethasone in newly diagnosed transplant‐ineligible myeloma. Real‐world experience: Data from a Single Centre in North Wales, UK

C. Arachchilage - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Single centre retrospective cohort study of the occurrence of venous thromboembolism in patients receiving immunomodulator‐based therapy for the treatment of multiple myeloma

S. A. Bassiony - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Angiology

Venous thrombosis

Dexamethasone

Use of imaging in the management of newly diagnosed patients with myeloma at St. George's Hospital

K. Xu - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Plasmacytoma

N/A

Dynamic changes in serum complements during chemotherapy in patients with multiple myeloma and their correlations with disease markers

S. K. Nagumantry - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

HaemBase Cymru (HBC): an electronic data collection platform for patients treated with haematological malignancies in Wales

C. Bygrave - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Quality improvement project for the treatment of myeloma‐related bone disease in Nottingham University Hospitals Trust

M. Georgiou - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Smoldering myeloma

Zoledronic acid

A retrospective review of antimicrobial use and risk stratification of patients with multiple myeloma admitted due to suspected infection

S. Raffles - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hypogammaglobulinaemia

Piperacillin/tazobactam

Myeloma in Northland 2016–2017: incidence, risk factors and outcome

L. Chen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

The use of urine Bence‐Jones protein testing in the investigation of a new paraprotein – a DGH perspective

A. Aggarwal - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Myeloma UK: outline of the Clinical Service Excellence Programme (CSEP)

S. Renwick - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Osteonecrosis of the jaw secondary to bisphosphonate treatment in multiple myeloma – real‐world data

L. Vanhinsbergh - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Multiple Myeloma

Zoledronic acid

Evaluating the role of the Myeloma UK, Myeloma Infoline in the provision of personalised information and care for myeloma patients and their families

S. Quinn - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Methadone hydrochloride

A retrospective single centre cohort study of the efficacy of weekly subcutaneous bortezomib containing treatment regimes in the management of plasma cell disorders

S. Bassiony - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Cyclophosphamide

Filters

45280 Abstracts